The Incretin Space
A collection of collated data on incretin drug developments, including new drugs, new treatments and the future of incretins in medicine
Written by
The Incretin Space
Archive
GLP-1
+3
Jul 28, 2026
•
7 min read
Retatrutide revolution continues
Weight loss remains the star of the show, but cardiovascular data was underpowered
GLP-1
+1
Jul 16, 2026
•
10 min read
What is the deal with liver concerns in small molecule GLP-1s?
A guest post by Jen Can NuSH on liver concerns and small molecule GLP1 medications
GLP-1
+3
Jul 2, 2026
•
14 min read
ADA Conference 2026: Zenagamtide, Berobenatide, UBT251, enicepatide & orforglipron
Orals, Triples, Biologics and even more data from ADA 2026
GLP-1
+4
Jul 1, 2026
•
5 min read
Eloralintide + Tirzepatide = Bariatric Surgery results!
New phase 1b data shows incredible weight loss
GLP-1
+2
Jun 19, 2026
•
18 min read
ADA Conference 2026: CagriSema & Survodutide
A tale of dual agonists, glucagon or amylin, who wins the insulin sensitivity race?
GLP-1
+3
Jun 9, 2026
•
12 min read
ADA 2026: Retatrutide Revolution
A paradigm shift in diabetes and obesity arrives!
GLP-1
+6
May 29, 2026
•
10 min read
ADA Conference 2026 Preview
The Super Bowl Conference for diabetes and incretins!
